siRNA, miRNA, and shRNA: In vivo applications

Journal of Dental Research

Volumn 87, Issue 11, 2008, Pages 992-1003

  Pushparaj, P N ^a,b   Aarthi, J J ^a   Manikandan, J ^a   Kumar, S D ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Caenorhabditis elegans; Gene silencing; In vivo; microRNAs; RNA activation; RNA interference; Short hairpin RNAs; Small interfering RNAs

Indexed keywords

MICRORNA; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA;

ANIMAL; BIOSYNTHESIS; DRUG DESIGN; GENE SILENCING; GENE THERAPY; GENE VECTOR; GENERAL ASPECTS OF DISEASE; GENETICS; HUMAN; INVERTED REPEAT; REVIEW; RNA INTERFERENCE; TRANSCRIPTION INITIATION;

ANIMALS; DISEASE; DRUG DESIGN; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GENETIC VECTORS; HUMANS; INVERTED REPEAT SEQUENCES; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-INDUCED SILENCING COMPLEX; TRANSCRIPTIONAL ACTIVATION;

EID: 58149242904     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910808701109     Document Type: Article

References (135)

1. Aagaard L, Rossi JJ (2007). RNAi therapcutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75-86.
2. Amarzguioui M, Holen T, Babaie E, Prydz H (2003), Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31:589-595.
3. Ambros V (2004). The functions of animal microRNAs, Nature 431:350-Azzouz M (2006). Gene therapy for ALS: progress and prospects. Biochim Biophys Acta 1762:1122-1127.
4. Baglioni C (1979). Interferon-induced enzymatic activities and their role in the antriviral state. Cell 17:255-264.
5. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
6. Beertsen W, McCulloch CA, Sodek J (1997). The periodontal ligament: a unique, multifunctional connective tissue. Periodontal 2000 13:20-40.
7. Bernards R, Brummelkamp TR, Beijersbergen RL (2006). shRNA libraries and their use in cancer genetics. Nat Methods 3:701-706.
8. Bernstein E, Caudy AA, Hammond SM, Hannon OJ (2001a). Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366.
9. Bernstein E, Denli AM, Hannon GJ (2001b). The rest is silence. RNA 7:1509-1521.
10. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcom H, Li MZ, et al. (2003). Dicer is essential for mouse development. Nat Genet 35:215-217.
11. Bohnsack MT, Czaplinski K, Gorlich D (2004). Exportin 5 is a RanGTP-+ dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10:185-191.
12. Calin GA, Croce CM (2006a). MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66:7390-7394. Calin GA, Croee CM (2006b). MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866.
13. Calin GA, Dumitm CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. (2002). Frequent deletions and down-regulation of miero-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524-15529.
14. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:2999-3004.
15. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA (2001). Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 98:9742-9747.
16. Chang K, Elledge SJ, Hannon GJ (2006). Lessons from nature: microRNA-based shRNA libraries. Nat Methods 3:707-714.
17. Cheek E (2007). RNA interference: hitting the on switch. Nature 448:855-858.
18. Chen YJ, Chang JT, Lee L, Wang HM, Liao CT, Chiu CC, et al. (2007). DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 26:467-476.
19. Chiu YL, Rana TM (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9:1034-1048.
20. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ (2004). Processing of primary microRNAs by the microprocessor complex. Nature 432:231-235.
21. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, et al. (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104:17204-17209.
22. Eis PS, Tarn W, Sun L, Chadbum A, Li Z, Gomez MF, et al. (2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102:3627-3632.
23. Elbashir SM, Harborth J, Weber K, Tuschl T (2002). Analysis of gene fonction in somatic mammalian cells using small interfering RNAs. Methods 26:199-213.
24. Esau CC, Monia BP (2007). Therapeutic potential for microRNAs. Adv Drug Deliv Rev 59:101-114.
25. Esau C, Rang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, et al. (2004). MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 279:52361-52365.
26. Escoffre JM, Debin A, Reynes JP, Drocourt D, Tiraby G, Hellaudais L, et al. (2008). Long-lasting in vivo gene silencing by eleclrotransfer of shRNA expressing plasmid. Technol Cancer Res Treat 7:109-116.
27. Faustino NA, Cooper TA (2003). Pre-mRNA splicing and human disease. Genes Dev 17:419-437.
28. Fewell GD, Schmitt K (2006). Vector-based RNAi approaches for stable, inducible and genome-wide screens. Drug Discov Today 11:975-982.
29. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
30. Garber K (2006). Genetics. Small RNAs reveal an activating side. Science 314:741-742.
31. Garcia-Blanco MA, Baraniak AP, Lasda EL (2004). Alternative splicing in disease and therapy. Nat Biotechnol 22:535-546.
32. Golzio M, Teissie J (2008). Optical in vivo imaging of electrically mediated delivery of siRNA into muscle for gene function analysis. Methods Mol Biol 423:279-287.
33. Golzio M, Mazzolini L, Moller P, Rols MP, Teissie J (2005). Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther 12:246-251.
34. Gregory RI, Yan KP, Amuthan G, Chcndrimada T, Doratotaj B, Cooch N, et al. (2004). The microprocessor complex mediates the genesis of microRNAs. Nature 432:235-240.
35. Gregory RI, Chcndrimada TP, Cooch N, Shiekhattar R (2005). Human RISC couples microRNA biogenesis and posltranscriptional gene silencing. Cell 123:631-640.
36. Grishok A (2005). RNAi mechanisms in Caenorhabditis elegans. FEBS Lett 579:5932-5939.
37. Grishok A, Tabara H, Mello CC (2000). Genetic requirements for inheritance of RNAi in C. elegans. Science 287:2494-2497.
38. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, et al. (2001). Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106:23-34.
39. Hammond SM, Bernstein E, Beach D, Hannon GJ (2000). An RNA-directed nuclease mediates post-transeriptional gene silencing in Drosophila cells. Nature 404:293-296.
40. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN (2004). The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 18:3016-3027.
41. Hannon GJ, Rossi JJ (2004). Unlocking the potential of the human genome with RNA interference. Nature 431:371-378.
42. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringc SA, Weber K, et al. (2003). Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing, Antisense Nucleic Acid Drug Dev 13:83-105.
43. Harfe BD (2005). MicroRNAs in vertebrale development. Curr Opin Genet Dev 15:410-415.
44. Hatfield S, Ruohola-Baker H (2008). microRNA and stern cell function. Cell Tissue Res 331:57-66.
45. Holen T (2006). Efficient prediction of siRNAs with siRNArulcs 1.0: an open-source JAVA approach to siRNA algorithms. RNA 12:1620-1625.
46. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H (2002). Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res 30:1757-1766.
47. Hong J, Qian Z, Shen S, Min T, Tan C, Xu J, et al. (2005), High doses of siRNAs induce eri-1 and adar-1 gene expression and reduce the efficiency of RNA interference in the mouse. Biochem J 390(Pt 3):675-679.
48. Honma K, Takeshita F, Ochiya T (2007). [Application of atelocollagen-mediated si RNA delivery for RNAi therapies]. Yalmgaku Zasshi 127:807-812 [article in Japanese].
49. Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, et al. (2004). A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res 32:893-901.
50. Huang F, Khvorova A, Marshall W, Sorkin A (2004). Analysis of elathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference. J Biol Chem 279:16657-16661.
51. Hulvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD (2001). A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-? small temporal RNA. Science 293:834-838.
52. Hutvagner G, Simard MJ, Mello CC, Zamore PD (2004). Sequence-specific inhibition of small RNA function, PLoS Biol 2(4):E98.
53. Janowski BA, Hu J, Corey DR (2006). Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids arid duplex RNAs. Nat Protoc 1:436-443.
54. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR (2007). Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 3:166-173.
55. Jod JY, Shi Y, Zhou YQ, Tian Y, Shen L, Liu Y, et al. (2007). [Experimental siCD44-targeted therapy of human nasopharyngeal carcinoma mediated by adenovirus]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 29:626-630 [article in Chinese].
56. Kenyon C (1988). The nematode Caenorhabditis elegans. Science 240:1448 1453.
57. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH (2001). Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 15:2654-2659.
58. Khvorova A, Reynolds A, Jayasena SD (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115:209-216.
59. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23:222-226.
60. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, et al (2007). Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 15:1145-1152.
61. Kim VN (2005). Small RNAs: classification, biogenesis, and function. Mol Cells 19:1-15.
62. Kim WJ, Christensen LV, Jo S, Yockman JW, Jeong JH, Kim YH, et al. (2006). Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 14:343-350.
63. Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M, Takata T (2005a). Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol Cancer Ther 4:471-476.
64. Kudo Y, Kitajima S, Ogawa I, Miyauehi M, Takata T (2005b). Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma. Oral Oncol 41:105-116.
65. Lai WQ, Goh HH, Bao Z, Wong WS, Melendez AJ, Leung BP (2008). The role of sphingosine kinase in a murine model of allergic asthma. J Immunol 180:4323-4329.
66. Landthaler M, Yalein A, Tuschl T (2004). The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 14:2162-2167.
67. Lee MS, Wajnarajch MP, Kim SS, Plotnick LP, Wang J, Gertner JM, et al. (2000). Autosomal dominant growth hormone (GH) deficiency type II: the Del32-71-GH deletion mutant suppresses secretion of wild-type GH. Endocrinology 141:883-890.
68. Lee Y, Kim M, Han J, Yeom KH, Lee S, Back SH, et al. (2004). MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23:4051-4060.
69. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H (2002), Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 32:107-108.
70. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, et al. (2006). Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 103:17337-17342.
71. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435:834-838.
72. Lu PY, Xie F, Woodle MC (2005). In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 54:117-142.
73. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U (2004). Nuclear export of microRNA precursors. Science 303:95-98.
74. Manikandan J, Pushparaj PN, Melendez AJ (2007). Protein i: interference at protein level by inirabodies. Front Biosci 12:1344-1352.
75. Martin SE, Caplen NJ (2007). Applications of RNA interference in mammalian systems. Annu Rev Genomics Hum Genet 8:81-108.
76. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, et al. (2002). Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16:2385-2390.
77. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD (2005). Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123:607-620.
78. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, et al. (2003). Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21:63 9-644.
79. McManus MT (2003). MicroRNAs and cancer. Semin Cancer Biol 13:253-258.
80. Melendez AJ, Hamett MM, Pushparaj PN, Wong WS, Tay HR, McSharry CP, et al. (2007). Inhibition of Fe epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes. Nat Med 13:1375-1381.
81. Minakuchi Y, Takcshita F, Kosaka N, Sasaki H, Yamamolo Y, Kouno M, et al. (2004). Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32:e109.
82. Minks MA, West DK, Benvin S, Baglioni C (1979). Structural requirements of double-stranded RNA for the activation of 2′,5′-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J Biol Chem 254:10180-10183.
83. Monson JP (2003). Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 148(Suppl 2):9-14.
84. Neely LA, Patel S, Garver J, Gallo M, Hackett M, McLaughlin S, et al. (2006). A single-molecule method for the quantitation of microRNA gene expression. Nat Methods 3:41-46.
85. Nykanen A, Haley B, Zamore PD (2001), ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107:309-321.
86. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007). MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl A cad Sci USA 104:1604-1609.
87. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nieoll J, et al. (2008). Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205:585-594.
88. Ochiya TH, Honma K, Takcshita F, Nagahara S (2007). Atelocollagen- mediated drug discovery technology. Expert Opin Drug Dlscov 2:159-167.
89. Pitsch S, Weiss PA (2001). Chemical synthesis of RNA-sequences with 2′-0-[(triisopropylsilyl)oxy]methyT-protected ribonucleoside phosphoramidites (=TOM-phosphoramidites) (Unit 3.9). In: Current protocols of nucleic acid chemistry. Beaucagc S, editor. New York, NY: John Wiley & Sons, Inc.
90. Pitsch S, Weiss PA, Wu X, Ackermann D, Honegger T (1999). Fast and reliable automated synthesis of RNA and partially 2′-0-protccted precursors ("caged RNA") based on two novel, orthogonal 2′-0-protecting groups. Helv Chim Acta 82:1753-1761.
91. Pitsch S, Weiss PA, Jenny L, Stutz A, Wu X (2001). Reliable chemical synthesis of oligoribonucleotides (RNA) with 2′-0-[(triisopropylsilyl) oxy]methyl (2′-0-TOM) protected phosphoramiditcs. Helv Chim Acta 84:3773-3795.
92. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, et al. (2004). A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432:226-230.
93. Poy MN, Spranger M, Stoffel M (2007). mieroRNAs and the regulation of glucose and lipid metabolism. Diabetes Obes Metab 9(Suppl 2):67-73.
94. Pushparaj PN, Melendez AJ (2006). Short interfering RNA (siRNA) as a novel therapeutic. Clin Exp Pharmacol Physiol 33:504-510.
95. Pushparaj PN, Aarthi JJ, Kumar SD, Manikandan J (2008a). RNAi and RNAa - the Yin and Yang of RNAomc. Bioinformation 2:235-237.
96. Pushparaj PN, H'ng SC, Melendez AJ (2008b). Refining siRNA in vivo transfection: Silencing SPHK1 reveals its key role in C5a-induced inflammation in vivo. Int J Biochem Cell Biol 40:1817-1825.
97. Rand TA, Petersen S, Du F, Wang X (2005). Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123:621-629.
98. Reid T, Warren R, Kirn D (2002). Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9:979-986.
99. Reynolds A, Leake D, Boese Q, Searinge S, Marshall WS, Khvorova A (2004). Rational siRNA design for RNA interference. Nat Biotechnol 22:326-330.
100. Ryther RC, Flynt AS, Harris BD, Phillips JA 3rd, Patton JG (2004). GH1 splicing is regulated by multiple enhancers whose mutation produces a dominant-negative GH isoform that can be degraded by allcle-specific small interfering RNA (siRNA). Endocrinology 145:2988-2996.
101. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R, Deissler H (2002). Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumour Biol 23:139-145.
102. Service RF (2006). Gene sequencing. The race for the $1000 genome. Science 311:1544-1546.
103. Shi Y, Tian Y, Zhou YQ, Ju JY, Liu Y, Zhu LP (2007a). [Reduction of CD44 expression results in growth inhibition of human nasopharyngeal carcinoma cell CNE-2L2 in vitro]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 29:67-72 [article in Chinese].
104. Shi Y, Tian Y, Zhou YQ, Ju JY, Qu L, Chen SL, et al. (2007b). Inhibition of malignant activities of nasopharyngeal carcinoma cells with high expression of CD44 by siRNA. Oncol Rep 18:397-403.
105. Siolas D, Lcrner C, Burehard J, Ge W, Linsley PS, Paddison PJ, et al. (2005). Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23:227-231.
106. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoom DM, et al. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709-717.
107. Song Y, Zhang Z, Yu X, Yan M, Zhang X, Gu S, et al. (2006). Application of lentivirus-mediated RNAi in studying gene function in mammalian tooth development. Dev Dyn 235:1334-1344.
108. Sorensen DR, Leirdal M, Sioud M (2003). Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327:761-766.
109. Tabara H, Yasuda J (2003). [Physiological and technological aspects of RNAi]. Tanpakushitsu Kakusan Koso 48(4 Suppl):469-479 [article in Japanese].
110. Tabara H, Yigit E, Siomi H, Mello CC (2002). The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DExH-box helicase to direct RNAi in C. elegans. Cell 109:861-871.
111. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006). NF-kappaB-dependenl induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sei USA 103:12481-12486.
112. Taganov KD, Boldin MP, Baltimore D (2007). MieroRNAs and immunity: tiny players in abig field. Immunity 26:133-137.
113. Takeshita F, Ochiya T (2006). Therapeutic potential of RNA interference against cancer. Cancer Sci 97:689-696.
114. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, et al. (2005). Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102:12177-12182.
115. Thomas M, Lu JJ, Chen J, Klibanov AM (2007). Non-viral siRNA deliver}' to the lung. Adv Drug Deliv Rev 59:124-133.
116. Timmons L, Tabara H, Mello CC, Fire AZ (2003). Inducible systemic RNA silencing in Caenorhabditis elegans. Mol Biol Cell 14:2972-2983.
117. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. (2006). A signature pattern of stress-responsive mieroRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103:18255-18260.
118. Victor M, Bei Y, Gay F, Calvo D, Mello C, Shi Y (2002). HAT activity is essential for CBP-1-dependent transcription and differentiation in Caenorhabditis elegans. EMBO Rep 3:50-55.
119. Vlasenko LP, Melendez AJ (2005). A critical role for sphingoslne kinase in anaphylatoxin-induced neutropenia, peritonitis, and cytokine production in vivo. J Immunol 174:6456-6461.
120. Vomlocher HP (2006). Antibody-directed cell-type-specific delivery of siRNA. Trends Mol Med 12:1-3.
121. Wang H, Ghosh A, Baigude H, Yang CS, Qiu L, Xia X, et al. (2008). Therapeutic gene silencing delivered by a chemically modified siRNA against mutant SOD1 slows ALS progression. J Biol Chetn 283:15845-15852.
122. Wang J, Barr MM (2005). RNA Interference in Caenorhabditis elegans. Methods Enzymol 392:36-55.
123. Watanabe T, Umehara T, Yasui F, Nakagawa SI, Yano J, Ohgi T, et al. (2007). Liver target delivery of small interfering RNA to the HCV gene by laetosylated eationie liposome. J Hepatol 47:744-750.
124. Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N, et al. (2007). MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 282:12363-12367.
125. Xie FY, Woodle MC, Lu PY (2006). Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 11:67-73.
126. Yamada S, Murakami S, Matoba R, Ozawa Y, Yokokoji T, Nakahira Y, et al. (2001). Expression profile of active genes in human periodontal ligament and isolation of PLAP-1, a novel SLRP family gene. Gene 275:279-286.
127. Yamada S, Tomoeda M, Ozawa Y, Yoneda S, Terashima Y, Ikezawa K, et al. (2007). PLAP-1/asporin, a novel negative regulator of periodontal ligament mineralization. J Biol Chem 282:23070-23080.
128. Yanamoto S, Iwamoto T, Kawasaki G, Yoshitomi I, Baba N, Mizuno A (2005). Silencing of the p53R2 gene by RNA Interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett 223:67-76.
129. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13:486-491.
130. Ye P, Nadkarni MA, Hunter N (2006). Regulation of E-eadherin and TGF-beta3 expression by CD24 in cultured oral epithelial cells. Biochem Biophys Res Commun 349:229-235.
131. Yi R, Qin Y, Macara IG, Cullen BR (2003). Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17:3011 -3016.
132. Zhang S, Zhao B, Jiang H, Wang B, Ma B (2007). Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 123:1-10.
133. Zhao Z, Cao Y, Li M, Meng A (2001). Double-stranded RNA injection produces non-specific defects in zebrafish. Dev Biol 229:215-223.
134. Zhao Y, Samal E, Srivastava D (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436:214-220.
135. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, et al. (2007). Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1 -2. Cell 129:303-317.